GM-CT-01

DRUG3 trials

Sponsors

Galectin Therapeutics Inc.

Conditions

Breast CancerCancer of the Bile DuctColorectal CancerGallbladder CancerHead and Neck CancerLung CancerProstate Cancer

Phase 1

Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

CompletedNCT00054977

Galectin Therapeutics Inc.Breast Cancer, Colorectal Cancer, Head and Neck Cancer +2

Start: 2003-02-28End: 2006-09-30Updated: 2012-03-12

Phase 2

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

WithdrawnNCT00386516

Galectin Therapeutics Inc.Cancer of the Bile Duct, Gallbladder Cancer

Start: 2006-09-30End: 2009-06-30Updated: 2017-08-01

A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer

WithdrawnNCT00388700

Galectin Therapeutics Inc.Colorectal Cancer

Start: 2006-10-31End: 2009-06-30Updated: 2018-02-14